205 related articles for article (PubMed ID: 31502525)
1. Insurance Status Is Associated with Extent of Treatment for Patients with Papillary Thyroid Carcinoma.
Ullmann TM; Gray KD; Limberg J; Stefanova D; Moore MD; Buicko J; Finnerty B; Zarnegar R; Fahey TJ; Beninato T
Thyroid; 2019 Dec; 29(12):1784-1791. PubMed ID: 31502525
[No Abstract] [Full Text] [Related]
2. Insurance type is associated with appropriate use of surgical and adjuvant care for differentiated thyroid carcinoma.
Thiesmeyer JW; Limberg J; Ullmann TM; Greenberg JA; Egan CE; Moore M; Finnerty BM; Laird AM; Zarnegar R; Fahey TJ; Beninato T
Surgery; 2022 Jan; 171(1):140-146. PubMed ID: 34600741
[TBL] [Abstract][Full Text] [Related]
3. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
4. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage.
Zambeli-Ljepović A; Wang F; Dinan MA; Hyslop T; Roman SA; Sosa JA; Scheri RP
J Surg Res; 2019 Nov; 243():189-197. PubMed ID: 31185435
[TBL] [Abstract][Full Text] [Related]
5. Trends in the Management of Localized Papillary Thyroid Carcinoma in the United States (2000-2018).
Pasqual E; Sosa JA; Chen Y; Schonfeld SJ; Berrington de González A; Kitahara CM
Thyroid; 2022 Apr; 32(4):397-410. PubMed ID: 35078347
[No Abstract] [Full Text] [Related]
6. Disparity in the use of adjuvant radioactive iodine ablation among high-risk papillary thyroid cancer patients.
Moten AS; Zhao H; Intenzo CM; Willis AI
Eur J Surg Oncol; 2019 Nov; 45(11):2090-2095. PubMed ID: 31253543
[TBL] [Abstract][Full Text] [Related]
7. Aggressive variants of papillary thyroid microcarcinoma are associated with extrathyroidal spread and lymph-node metastases: a population-level analysis.
Kuo EJ; Goffredo P; Sosa JA; Roman SA
Thyroid; 2013 Oct; 23(10):1305-11. PubMed ID: 23600998
[TBL] [Abstract][Full Text] [Related]
8. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan MA; Perkins JM; Roman SA; Sosa JA
Endocrine; 2016 Jun; 52(3):579-86. PubMed ID: 26708045
[TBL] [Abstract][Full Text] [Related]
9. Is There an Association Between Insurance Status and Survival and Treatment of Primary Bone and Extremity Soft-tissue Sarcomas? A SEER Database Study.
Smartt AA; Jang ES; Tyler WK
Clin Orthop Relat Res; 2020 Mar; 478(3):527-536. PubMed ID: 31390340
[TBL] [Abstract][Full Text] [Related]
10. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis.
Halpern MT; Ward EM; Pavluck AL; Schrag NM; Bian J; Chen AY
Lancet Oncol; 2008 Mar; 9(3):222-31. PubMed ID: 18282806
[TBL] [Abstract][Full Text] [Related]
11. Association of medicaid expansion of the Affordable Care Act with the stage at diagnosis and treatment of papillary thyroid cancer: A difference-in-differences analysis.
Limberg J; Stefanova D; Thiesmeyer JW; Ullmann TM; Bains S; Finnerty BM; Zarnegar R; Li J; Fahey Iii TJ; Beninato T
Am J Surg; 2021 Sep; 222(3):562-569. PubMed ID: 33541689
[TBL] [Abstract][Full Text] [Related]
12. Access denied: The relationship between patient insurance status and access to high-volume hospitals.
Nabi J; Tully KH; Cole AP; Marchese M; Cone EB; Melnitchouk N; Kibel AS; Trinh QD
Cancer; 2021 Feb; 127(4):577-585. PubMed ID: 33084023
[TBL] [Abstract][Full Text] [Related]
13. Treatment variation by insurance status for breast cancer patients.
Coburn N; Fulton J; Pearlman DN; Law C; DiPaolo B; Cady B
Breast J; 2008; 14(2):128-34. PubMed ID: 18315690
[TBL] [Abstract][Full Text] [Related]
14. Lymphovascular invasion is associated with survival for papillary thyroid cancer.
Pontius LN; Youngwirth LM; Thomas SM; Scheri RP; Roman SA; Sosa JA
Endocr Relat Cancer; 2016 Jul; 23(7):555-62. PubMed ID: 27317633
[TBL] [Abstract][Full Text] [Related]
15. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
[TBL] [Abstract][Full Text] [Related]
16. The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years.
Fletcher SA; Cole AP; Lu C; Marchese M; Krimphove MJ; Friedlander DF; Mossanen M; Kilbridge KL; Kibel AS; Trinh QD
Cancer; 2020 Feb; 126(3):496-505. PubMed ID: 31626340
[TBL] [Abstract][Full Text] [Related]
17. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
18. Relationship between insurance status and interhospital transfers among cancer patients in the United States.
Rubens M; Ramamoorthy V; Saxena A; Appunni S; Sundil S; Veledar E; McGranaghan P; Tonse R; Fitz SJT; Chuong MD; Odia Y; Kotecha R; Mehta MP; Kotecha R
BMC Cancer; 2022 Jan; 22(1):121. PubMed ID: 35093015
[TBL] [Abstract][Full Text] [Related]
19. Health Insurance Affects Head and Neck Cancer Treatment Patterns and Outcomes.
Inverso G; Mahal BA; Aizer AA; Donoff RB; Chuang SK
J Oral Maxillofac Surg; 2016 Jun; 74(6):1241-7. PubMed ID: 26851312
[TBL] [Abstract][Full Text] [Related]
20. Impact of payer status on survival in parotid malignancy.
Stubbs VC; Rajasekaran K; Chen J; Cannady SB; Brant JA; Newman JG
Am J Otolaryngol; 2019; 40(4):555-559. PubMed ID: 31097206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
